Myeloproliferative Neoplasms

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.

Yue Wei, PhD, discusses how HMAs promote late-stage megakaryocyte maturation and platelet production in MDS mouse models.

Nuvisertib was well tolerated with no dose-limiting toxicities and promising efficacy in relapsed/refractory myelofibrosis.

Guillermo Garcia-Manero, MD, discusses the rationale and design of the GLORA-4 trial evaluating lisaftoclax plus azacitidine in high-risk MDS.

WJ01024 alone and in combination with ruxolitinib was safe and generated efficacy signals in relapsed/refractory myelofibrosis.

Yue Wei, PhD, discusses the correlation between TET2 mutations and platelet recovery in patients with MDS receiving hypomethylating agents.

The FDA has granted orphan drug designation to zavabresib for the treatment of patients with myelofibrosis.

Dr Garcia-Manero contextualizes lisaftoclax's potential to improve outcomes historically achieved with azacitidine alone in higher-risk MDS.

Guillermo Garcia-Manero, MD, discusses how updated VERONA trial data showed no OS benefit with venetoclax plus azacitidine vs azacitidine alone in MDS.

Yue Wei, PhD, discussed the role of HMAs in platelet response in MDS and the clinical relevance of using a mouse model to investigate this approach.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

The first-in-class, CXCR4hi regulatory T-cell therapy CK0804 received orphan drug designation for patients with myelofibrosis.

The FDA has received a new drug application seeking the approval of rusfertide for the treatment of adult patients with polycythemia vera.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Ayalew Tefferi, MD, tirelessly advances medicine, driven by a philosophy that physical and intellectual journeys are one.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.

Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

The FDA has granted breakthrough therapy designation to INCA033989 in CALR-mutated essential thrombocythemia.

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations